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Background: Lycorine, a natural alkaloid extracted from Amaryllidaceae, has shown various pharmacological effects.
Recent studies have focused on the potential antitumor activity of lycorine. In our previous study, we found that
lycorine decrease the cell viability of leukemia HL-60 cells and multiple myeloma KM3 cells and induces cell
apoptosis. However, the effect and molecular mechanism of lycorine on human chronic myelocytic leukemia cells
has yet to be determined.
Methods: Human chronic myelocytic leukemia cells K562 were treated with lycorine. Cell viability was monitored
using the method of CCK-8. The histone deacetylase (HDAC) enzymatic activity was detected by HDAC colorimetric
assay, and the cell cycle was analyzed by flow cytometry. The expression of cell-cycle related proteins were
identified using Western blot.
Results: In the present study, we further revealed that lycorine can inhibit the proliferation of K562 cells. Analysis of
HDAC activity showed that lycroine decreases HDAC enzymatic activities in K562 cells in a dose-dependent manner.
Inhibition of HDAC activity has been associated with cell-cycle arrest and growth inhibition. We evaluated the cell
cycle distribution after lycorine treatment and found that lycorine causes cell-cycle arrest in the G0/G1 phase. To
investigate the mechanism behind this cell cycle arrest, G1-related proteins were assayed by Western blot. After
lycorine treatment, cyclin D1 and cyclin-dependent kinase 4 expressions were inhibited and retinoblastoma protein
phosphorylation was reduced. Lycorine treatment also significantly upregulated the expression of p53 and its target
gene product, p21.
Conclusions: These results suggest that inhibition of HDAC activity is responsible for at least part of the induction
of cell-cycle arrest in the G0/G1 phase by lycorine and provide a mechanistic framework for further exploring the
use of lycorine as a novel antitumor agent.
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Leukemia is a type of fatal hematological malignancy.
Human chronic myelocytic leukemia (CML), a common
type of leukemia, is a myeloproliferative disorder charac-
terized by increased proliferation of granulocytic cell
lines with loss capacity to differentiate. CML originates* Correspondence: yemaocsu@hotmail.com; jingliucsu@hotmail.com
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reproduction in any medium, provided the orfrom a constitutive activation of Bcr-Abl tyrosine kin-
ase, which develops from Philadelphia chromosome
translocation. Imatinib mesylate (Glivec), a selective
inhibitor of Bcr-Abl, was developed as the first molecule-
targeted anticancer drug to treat CML patients. However,
many patients report developing resistance to Glivec due
to mutations in the Abl kinase domain [1,2]. Considering
the difficulties inherent in the current CML therapy, the
discovery and development new treatment approaches for
CML treatment remains an urgent necessity.
Histone acetylation and deacetylation regulate the
chromatin structure and gene activation. Histone acetyl-
ation is catalyzed by histone acetyltransferases (HATs)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Lycorine decreases K562 cell growth. (A) Effect of
lycorine on the proliferation of K562 cells. Cells were cultivated in
RPMI 1640 medium with indicated concentrations of lycorine for 24,
48, and 72 h. The cell density was counted by manual cell counting.
(B) Effect of lycorine on the survival rate of K562 cells. Cells were
cultivated in RPMI 1640 medium with indicated concentrations of
lycorine for 24 and 48 h. The cell survival rate was calculated by
CCK-8 method. Each value represents the mean ± S.D. of three
independent experiments.
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histone deacetylation is mediated by histone deacetylases
(HDACs) and correlated with chromatin condensation
and transcriptional repression [3]. Both of these pro-
cesses play crucial roles in various biological functions,
including cell growth, differentiation, and apoptosis.
Dysregulation of these pathways contributes to human
cancer development. Several studies have indicated that
HDAC inhibitors, compounds that interfere with the
function of HDAC, exhibit antitumor activity against
various tumor cells by blocking cell cycle progression
and inducing apoptosis. Sodium butyrate, an HDAC in-
hibitor, can suppress breast cancer cell proliferation by
blocking the G1/S phase of the cell cycle and activating
the apoptosis pathway [4]. Two HDAC inhibitors, suber-
oylanilide hydroxamic acid (Vorinostat) and romidepsin
(Depsipeptide, FK228), were recently approved by the
U.S. Food and Drug Administration (USA) for the treat-
ment of cutaneous T-cell lymphoma [5].
Lycorine, a natural alkaloid extracted from Amarylli-
daceae, has shown various pharmacological effects, such
as anti-inflammatory activities, anti-malarial properties,
emetic actions, anti-virus effects, and so on [6,7]. Recent
studies have focused on the potential antitumor activity
of lycorine. Lycorine can reportedly inhibit the growth
of multiple tumor cells that are naturally resistant to
pro-apoptotic stimuli, such as glioblastoma, melanoma,
non-small-cell-lung cancers, and metastatic cancers,
among others. Furthermore, lycorine provides excellent
in vivo antitumor activity against the B16F10 melanoma
model [8]. In our previous study, we found that lycorine
decreases the survival rate of and induces apoptosis in
HL-60 acute myeloid leukemia cells and the multiple
myeloma cell line KM3. The mechanisms of the induced
apoptosis were mediated by stimulating the caspase
pathway and increasing the Bax: Bcl-2 ratio through
downregulation of Bcl-2 expression [9,10]. Lycorine also
exhibits significantly higher anti-proliferative activities in
tumor cells than in non-tumor cell lines [11].
In this study, we further reveal that lycorine can in-
hibit proliferation of the human CML cell line K562.
Analysis of HDAC activity shows that lycroine decreases
HDAC enzymatic activities in K562 cells in a dose-
dependent manner. To determine the effect of HDAC
inhibition, we evaluate the cell cycle distribution after
lycorine treatment. We show that lycorine inhibits the
proliferation of K562 cells through G0/G1 phase arrest,
which is mediated by the regulation of G1-related pro-
teins. After lycorine treatment, cyclin D1 and cyclin-
dependent kinase 4 (CDK4) expressions are inhibited
and retinoblastoma protein (pRB) phosphorylation is
reduced. Lycorine treatment also significantly upregu-
lates the expression of p53 and its target gene product,
p21. These results suggest that inhibition of HDACactivity is responsible for at least part of the induction of
G1 cell-cycle arrest of K562 cells by lycorine.Results
Lycorine inhibits the proliferation of K562 cells
To determine the effect of lycorine on the growth of
CML cells, K562 cells were treated with lycorine at vari-
ous concentrations and examined by manual cell count-
ing every 24 h for 72 h. Compared with the control
group, the cells density of the group treated with 5.0 μM
lycorine increased very slightly from 24 h to 72 h, which
indicates that lycorine significantly inhibits the growth
of K562 cells (Figure 1A). CCK-8 assays showed that the
viability of K562 cells exposed to various concentrations
of lycorine (1.25, 2.5, and 5.0 μM) decreased from 82%
to 54% after 24 h and from 80% to 42% after 48 h, which
reveals that lycorine inhibits the proliferation of K562
cells in a dose-dependent manner (Figure 1B).
Figure 3 Lycorine increases the proportion of G0/G1 phase
cells and decreases the proportion of G2/M phase cells. After
the K562 cells were cultivated with lycorine (5 μM), the percentage
of cells in the G1 phase increased gradually from 35.9% to 41.9%
after 24 h and the percentage of cells in the S phase increased
slightly from 51.7% to 53.6%. Asterisks (*) indicate significant
difference (P < 0.05) compared with the control group.
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Histone acetylation and deacetylation regulate the
chromatin structure and gene transcription. Dysregu-
lation of their function has been associated with
human cancer development. Recent studies have uti-
lized HDAC as a potential target for the develop-
ment of new therapeutic agents [3]. To determine
the effect of lycorine on HDACs, we detected the
expression of HDAC1 and HDAC3 proteins in K562
cells after lycorine treatment. We found that lycorine
did not change the expression of HDAC1 and
HDAC3 proteins (data not shown), whereas lycorine-
treated K562 cells significantly showed decreased
HDAC activity of 24 h after treatment (Figure 2).
These results reveal that lycroine directly inhibits HDAC
enzymatic activities but does not affect HDAC expres-
sion in K562 cells.Lycorine induces cell cycle arrest in the G0/G1 phase
Inhibition of HDAC activity has been associated with
cell-cycle arrest and growth inhibition. Thus, we deter-
mined whether or not lycorine can interfere with cell
cycle progression by flow cytometry. After K562 cells
were treated with 5 μM lycorine, the percentage of
cells in the G0/G1 phase increased significantly from
35.9% to 41.9% while S-phase cells showed only a
slight increased. The percentage of G2/M-phase cellsFigure 2 Effects of lycorine on the activity of HDACs in K562
cells. Briefly, nuclear proteins were extracted from K562 cells treated
with different concentrations of lycorine (2.5 or 5.0 μM) or without
lycorine for 24 h. About 50 μg of nuclear protein from each group
was added to a 96-well tissue culture plate and HDAC enzymatic
activities in the cell nucleus was determined according to the HDAC
colorimetric assay kit instructions. Values are expressed as the
percentage of HDAC activities relative to untreated cell extracts.
Results are presented as mean ± S.D. (n = 3, three independent
experiments). Asterisks (*) indicate significant difference (P < 0.05)
compared with the control group.decreased from 12.3% in the untreated group to 4.44% in
the treated group (Figure 3). This finding indicates that
cell cycle distribution was blocked significantly in the
G0/G1 phase when K562 cells are treated with lycorine.
Lycorine regulates the expression of cell cycle-related
proteins in K562 cells
To reveal the molecular mechanism of cell-cycle arrest
in the G0/G1 phase, we investigated whether or not the
effects induced by lycorine were associated with the level
of G1-S transition-related proteins. After treating K562
cells with various concentrations of lycorine, we
observed a dose-dependent decrease in cyclin D1 levels.
The decrease in cyclin D1 expression observed in
lycorine-treated cells was accompanied by a reduction in
the amount of CDK4 and CDK2 (Figure 4A and 4B). By
contrast, the expression patterns of cyclin E and CDK6
were not significantly altered after treatment with lycor-
ine (data not shown).
To examine the effect of lycorine on the phosphoryl-
ation of pRB, K562 cells were treated with different con-
centrations of lycorine, after which proteins were
detected using antibodies specific to the total pRB and
phosphorylated pRB. Results show that the expression of
total pRB remains almost unchanged but the level of
phosphorylated pRB decreases significantly in a dose-
dependent manner (Figure 5).
p21, as a CDK inhibitor, can interfere with cancer
cell cycle and affect cell proliferation [12]. p21 binds
to and inhibits the activity of cyclin E-CDK2 com-
plexes, which cause pRB hypophosphorylation and
cell-cycle arrest at the G1-S transition. We further
explored the expression of p21 at the protein level
and found that lycorine could induce a dose-dependent
Figure 4 Effects of lycorine on expression of cyclin D1, CDK4 and CDK2 in K562 cells. Tubulin was used for normalization and verification
of protein loading in Western blot analysis. Lanes 1, 2, 3, and 4 represent K562 cells treated with 0, 1.25, 2.5, and 5.0 μM lycorine, respectively.
Results are presented as mean ± S.D. (n = 3, three independent experiments). Asterisks (*) indicate significant difference (P < 0.05) compared with
the control group.
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with the change in p21, the expression of p53 pro-
tein was also elevated, which suggests that lycorine
induces the expression of p21 in a p53-dependent
manner in K562 cells (Figure 5).Figure 5 Effects of lycorine on expression of p21, p53 and pRB,
and phosphorylation of pRB in K562 cells. Lanes 1, 2, 3, and 4
represent K562 cells treated with 0, 1.25, 2.5, and 5.0 μM lycorine,
respectively. α-tubulin was used for normalization and verification of
protein loading in Western blot analysis. Results are presented as
mean ± S.D. (n = 3, three independent experiments).Discussion
HATs and HDACs regulate the chromatin structure and
gene transcription. Their dynamic balance plays a crucial
role in various biological functions, including cell prolif-
eration and death. Their dysregulation has been related
to the development and progression of various cancers,
including forms of myeloid leukemia [13,14]. Recent
studies have utilized HDACs as a promising target en-
zyme in anticancer drug development. Several studies
have shown that HDAC inhibitors can induce differenti-
ation of tumor cells, arrest the cell cycle at the G0/G1
phase, and activate the cell apoptosis gene. Normal cells
are relatively resistant to HDAC inhibitor-induced cell
death [15,16]. The results of our study reveal that lycor-
ine inhibits the activity of HDACs but does not affect
their expression in K562 cells, which indicates that
lycorine is a promising potential therapy agent in CML.
However, the detailed molecular mechanism behind the
inhibition of HDAC enzymatic activity by lycorine must
be investigated further.
Several studies have shown that inhibitors of HDAC
block cell cycle progression at the G0/G1 or G2/M
phase [17] depending on the cell type and type of drugs.
Similar to the effect of HDAC inhibitors in other tumor
types, lycorine inhibits cell cycle progression and
induces cell-cycle arrest in the G0/G1 phase in K562
cells. Progress in the eukaryotic cell cycle is driven by
protein kinase complexes consisting of a cyclin and a
CDK. During G1-phase progression, the complexes cyc-
lin D-CDK4, cyclin D-CDK6, and cyclin E-CDK2 are
activated and move the cell cycle from the G1 phase to
the S phase. We found that cyclin D1, CDK4 and CDK2
are significantly downregulated in K562 cells after lycor-
ine treatment. By contrast, the expression patterns of
cyclin E, CDK2, and CDK6 were not significantly altered
after lycorine treatment. This finding suggests that
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in lycorine-induced G0/G1 arrest in K562 cells.
During G1-phase progression, pRB is phosphorylated
by cyclin D-CDK4, CDK6, and cyclin E-CDK2 com-
plexes. Hyperphosphorylation of pRB inactivates its
function and dissociates the E2F transcription factor
from pRB, which is critical to progression to the S phase.
We found that, the expression level of pRB remains con-
stant in lycorine-treated K562 cells, whereas the level of
phosphorylated pRB decreases significantly, indicating
that lycorine can suppress pRB phosphorylation. Thus,
hypophosphorylated pRB combines E2Fs more tightly,
induces cell cycle arrest, and prevents proliferation.
CDK activity is regulated negatively by a group of pro-
teins called CDK inhibitors, including the protein p21
WAF1/CIP1 (p21). p21 protein binds to and inhibits the
activity of cyclin E-CDK2 complexes, which causes pRB
hypophosphorylation and cell cycle arrest in the G1–S
transition. Expression of the p21 gene is tightly con-
trolled by the tumor suppressor p53. The results of our
study show that lycorine treatment significantly upregu-
lates the expression of p21 in K562 cells. Consistent with
the change in p21, the expression of p53 protein is also
elevated, which suggests that lycorine may induce the
expression of p21 in a p53-dependent manner in K562
cells.
Conclusions
In summary, our data show that lycorine can inhibit
proliferation of the human CML cell line K562 through
G0/G1 phase arrest, which is mediated by the regulation
of G1-related protein. Meanwhile, the inhibition of
HDAC enzymatic activity is involved in the effect of
lycorine on K562 cells. Further in-depth in vivo studies
are presently under investigation in our laboratory.
Materials and methods
Cell culture and drugs
The human CML cell line K562 was purchased from
American Type Culture Collection and cultivated in
RPMI 1640 medium (Gibco) supplemented with 10%
heat-inactivated fetal bovine serum (Gibco), 100 U/mL
streptomycin, and 100 U/mL penicillin at 37°C in a
humidified atmosphere with 5% CO2. Cells were diluted
at a ratio of 1:3 every 1 d to 2 d. Lycorine (Sigma) was
dissolved at 0.034 M in dimethyl sulfoxide (DMSO;
Sigma) as a stock solution and diluted in serum-free
RPMI 1640 medium just before use. The maximum final
concentration of DMSO in medium was less than
0.02%.
Cell counting
To examine the anti-proliferative effect of lycorine,
growth curves were protracted by manual cell counting.Exponentially growing K562 cells treated with different
concentrations of lycorine (2.5 or 5.0 μM) or without
lycorine were cultivated at 5 × 105 cells/mL in a culture
flask (BioCoat). After appropriate culture, viable cells
were counted manually and continuously for up to 3 d.Cell viability and cytotoxicity assay (CCK-8)
Cell viability and cytotoxicity were measured with 2-
(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H tetrazolium monosodium salt (CCK-8)
assay as described previously. Briefly, exponentially grow-
ing K562 cells treated with various concentrations of
lycorine (1.25, 2.5, or 5.0 μM) or without lycorine were
cultivated at 1.25 × 104 cells/well in a 96-well tissue cul-
ture plate (BioCoat) at a total volume of 100 μL per well.
After cells were incubated for 24 and 48 h, 10 μL of
CCK-8 solution (Beyotime) was added to each well
and incubation of cells was performed for another 4 h
at 37°C. The relative cell viability was determined by
scanning with an ELISA reader with a 450 nm filter and
calculated by CCK-8 assay.Detection of HDAC activities
A HDAC colorimetric assay kit (Biovision) was applied
to determine HDAC enzymatic activities in the cell nu-
cleus according to the manufacturer’s instructions.
Briefly, proteins were extracted from K562 cells treated
with different concentrations of lycorine (2.5 or 5.0 μM)
or without lycorine for 24 h using a nuclear and cyto-
plasmic protein extraction kit (Beyotime) according to
manufacturer recommendations. About 50 μg of nuclear
protein from each group was added to a 96-well tissue
culture plate (BioCoat) at a final volume of 100 μL per
well. After incubation, HDAC activities were measured
by scanning with an ELISA reader with a 450 nm filter.
Values were expressed as the percentage of HDAC activ-
ities relative to the untreated cell extract.Flow cytometry
Flow cytometry was used to detect the cell cycle distri-
bution and quantitatively measure the apoptotic rate.
After K562 cells treated with lycorine (5.0 μM) or with-
out lycorine were cultivated at 5 × 105 cells/mL in each
culture flask (BioCoat) for 24 h, 1 × 106 cells were har-
vested and washed with PBS. The cells were then fixed
with ice-cold 70% ethanol at −20°C overnight. The next
day, the cells were washed with PBS, stained with
50 mg/mL propidium iodide (Sigma), and dissolved in
100 mg/L RNase A (Sigma). The sub-G1 peak (apoptosis
percentage) and cell cycle distribution were measured
with Cytomic FC 500 (Beckman Coulter) and analyzed
using Modifit LT software.
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Exponentially growing K562 cells treated with various
concentrations of lycorine (1.25, 2.5, or 5.0 μM) or with-
out lycorine were cultivated at 5 × 105 cells/mL in sev-
eral culture flasks (BioCoat). After 24 h of culture, the
cells were pelleted by centrifugation, washed three times
with PBS, resuspended in 100 μL of RIPA lysis buffer
(20 mM Tris–HCl, pH 7.5; 150 mM NaCl, 1 mM EDTA,
1% Nonidet P40, 0.5% deoxycholate, 0.1% SDS, 5 mM
NaF, and 0.5% cocktail), and centrifuged at 13000 rpm
and 4°C for 15 min to collect the supernatant. The
supernatant protein concentration was measured using a
bicinchoninic acid protein assay kit (Thermo Scientific).
Equal amounts of protein (50 μg) from each group were
electrophoresed for 2 h on 10% sodium dodecyl sulfate-
polyacrylamide gels and then transferred to a PVDF
membrane (Millipore) using an electroblotter for
100 min at 4°C. Membranes were blocked in PBS with
0.1% Tween 20 (PBST) containing 5% non-fat dried milk
power for 1 h. An antibody (Abcam) raised against
α-tubulin (1:20000), an antibody (Bioworld) raised
against pRB (1:2000), an antibody (Bioss) raised against
p21 an antibody (Cell Signaling) raised against phos-
phorylated pRB (1:3000), and antibodies (Santa Cruz
Biotech) raised against p53 (1:3000), cyclin D1 (1:200),
CDK4 (1:200), and CDK2 (1:500) were diluted in PBST
containing 5% non-fat milk and membranes were incu-
bated overnight at 4°C. After washing four times with
PBST for 10 min each time, the blot was incubated with
anti-mouse or anti-rabbit IgG conjugated with horserad-
ish peroxidase (Millipore, 1:5000 dilution in PBST con-
taining 5% non-fat milk) for 1 h at room temperature.
After washing three times with PBST for 10 min each
time, the blots were developed with a chemiluninescene
detection kit (ECL; Millipore), and the optical density of
each band was quantified by densitometric scanning.
Statistical analysis
The statistical difference between groups was deter-
mined by AVOVA and Tukey’s studentized range test.
Differences among groups were considered statistically
different at P < 0.05.
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